Torii Pharmaceutical
Advancing health through innovative therapies.
- Healthcare
- pharmaceutical
| JPY | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 | 2027 |
|---|---|---|---|---|---|---|---|
| Revenues | 0000 | 0000 | 0000 | 0000 | 0000 | 0000 | 0000 |
| % growth | 13 % | 4 % | 12 % | 11 % | 12 % | (1 %) | 2 % |
| EBITDA | 0000 | 0000 | 0000 | 0000 | 0000 | 0000 | 0000 |
| % EBITDA margin | 11 % | 12 % | 11 % | 13 % | 8 % | 6 % | 10 % |
| Profit | 0000 | 0000 | 0000 | 0000 | 0000 | 0000 | 0000 |
| % profit margin | 7 % | 8 % | 8 % | 8 % | 6 % | 5 % | 7 % |
| EV | 0000 | 0000 | 0000 | 0000 | 0000 | 0000 | 0000 |
| EV / revenue | 00.0x | 00.0x | 00.0x | 00.0x | 00.0x | 00.0x | 00.0x |
| EV / EBITDA | 00.0x | 00.0x | 00.0x | 00.0x | 00.0x | 00.0x | 00.0x |
| R&D budget | 0000 | 0000 | 0000 | 0000 | 0000 | 0000 | 0000 |
| R&D % of revenue | 2 % | 3 % | 6 % | 5 % | - | - | - |
Source: Company filings or news article, Equity research estimates
Related Content
Torii Pharmaceutical Co., Ltd. was founded in 1872 by Tokubei Torii in Yokohama, Japan. Originally established as Uenoya, the company began by importing pharmaceuticals from the West, marking the start of its long-standing presence in the pharmaceutical industry. Over the years, Torii Pharmaceutical evolved, focusing on the development and manufacturing of ethical pharmaceuticals, which are prescription drugs that require a medical prescription.
A significant milestone in Torii's journey occurred in May 2025, when Shionogi & Co., a major player in the pharmaceutical sector, announced its acquisition of Torii Pharmaceutical. This strategic move, valued at approximately 150 billion yen, was aimed at leveraging Torii's extensive sales network to enhance Shionogi's domestic reach and accelerate its global expansion, particularly in the antiviral drug market.
Throughout its history, Torii Pharmaceutical has been recognized for its commitment to innovation and quality in healthcare. The acquisition by Shionogi represents not only a new chapter in Torii's storied history but also a testament to its enduring impact on the pharmaceutical landscape in Japan and beyond. This acquisition is expected to bolster Shionogi's position in the market, while continuing Torii's legacy of providing high-quality pharmaceutical products.